TeSR™-E6

Defined, serum-free, xeno-free medium for pluripotent stem cells

Skip to the end of the images gallery

 

 

Skip to the beginning of the images gallery

TeSR™-E6

Defined, serum-free, xeno-free medium for pluripotent stem cells

From: 251 USD

Size

Choose an Option... 1 Kit

Size 1 Kit

Catalog #

(Select a product)

Defined, serum-free, xeno-free medium for pluripotent stem cells

Quantity

Add to Cart

By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.

Add to Wish List

What's Included

• TeSR™-E5/E6 Basal Medium, 475 mL

• TeSR™-E6 20X Supplement, 25 mL

Request Pricing

Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):

Estimated delivery time for your area

Product sample or exclusive offer

In-lab demonstration

By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.

• First Name
  Last Name
• Work Email Address
  Phone Number
• Company/Institution
  Zip/Postal Code
• Country

  Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegowina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France France, Metropolitan French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard and Mc Donald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Republic of Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar (Burma) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Republic of Serbia Reunion Romania Russia Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia South Africa South Georgia and South S.S. Spain Sri Lanka St. Helena St. Pierre and Miquelon Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Taiwan Tajikistan Tanzania, United Republic of Thailand The Democratic Republic of Congo Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu U.S. Minor Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City State Venezuela Vietnam Virgin Islands (British) Virgin Islands (U.S.) Wallis and Futuna Islands Western Sahara Yemen Zambia Zambrazo Zimbabwe
  State/Province/Region
• Comment
• I agree to receive future electronic communications from STEMCELL. I acknowledge that I can unsubscribe any time.
• 

Overview

Protocols and Documentation

Applications

Resources and Publications

Related Products

Overview

TeSR™-E6 is a defined, serum- and xeno-free medium that is based on the formulation of TeSR™-E8™, but does not contain transforming growth factor β (TGF-β) or basic fibroblast growth factor (bFGF). It may be used as a basal medium for differentiation of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, or other applications where removal of the above cytokines is desirable.

Subtype

Specialized Media

Cell Type

Pluripotent Stem Cells

Species

Human

Application

Cell Culture, Characterization, Differentiation

Brand

TeSR

Area of Interest

Drug Discovery and Toxicity Testing, Stem Cell Biology

Formulation Category

Serum-Free, Xeno-Free

View More View Less

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

TeSR™-E6

Catalog #

05946

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

TeSR™-E6

Catalog #

05946

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

TeSR™-E6

Catalog #

05946

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

TeSR™-E6

Catalog #

05946

Lot #

All

Language

English

View More View Less

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area

Workflow Stages

Workflow Stages for Human Pluripotent Stem Cell Research

Reprogramming

Maintenance

Differentiation

Workflow Stages for hPSC-Derived Endoderm Cell Research

Endoderm Induction

Characterization and Isolation

Downstream Differentiation

Workflow Stages for hPSC-Derived Mesoderm Cell Research

Mesoderm Induction

Downstream Differentiation

View More View Less

Resources and Publications

Educational Materials (4)

Brochure

Products for Human Pluripotent Stem Cells

Brochure

qPCR Arrays for Cell Characterization

Brochure

Maximize Your Pluripotential with the TeSR™ Family of hPSC Culture Media

Wallchart

Directed Differentiation of Pluripotent Stem Cells

Publications (1)

α-Ketoglutarate Accelerates the Initial Differentiation of Primed Human Pluripotent Stem Cells. TeSlaa T et al. Cell metabolism 2016 SEP

Abstract

Pluripotent stem cells (PSCs) can self-renew or differentiate from naive or more differentiated, primed, pluripotent states established by specific culture conditions. Increased intracellular α-ketoglutarate (αKG) was shown to favor self-renewal in naive mouse embryonic stem cells (mESCs). The effect of αKG or αKG/succinate levels on differentiation from primed human PSCs (hPSCs) or mouse epiblast stem cells (EpiSCs) remains unknown. We examined primed hPSCs and EpiSCs and show that increased αKG or αKG-to-succinate ratios accelerate, and elevated succinate levels delay, primed PSC differentiation. αKG has been shown to inhibit the mitochondrial ATP synthase and to regulate epigenome-modifying dioxygenase enzymes. Mitochondrial uncoupling did not impede αKG-accelerated primed PSC differentiation. Instead, αKG induced, and succinate impaired, global histone and DNA demethylation in primed PSCs. The data support αKG promotion of self-renewal or differentiation depending on the pluripotent state.

View publication

View All Publications

Related Products

Related Products

1. 

   TeSR™-E5

   Defined, serum-free, xeno-free medium for pluripotent stem cells

Item added to your cart

TeSR™-E6

Legal Statement:

This product was developed under license to intellectual property owned by WiCell™ Research Institute. This product is sold for research use only (whether the buyer is an academic or for-profit entity) under a non-transferable, limited-use license. Purchase of this product does not include the right to sell, use or otherwise transfer this product for commercial purposes (i.e., any activity undertaken for consideration, such as use of this product for manufacturing, or resale of this product or any materials made using this product, or use of this product or any materials made using this product to provide services) or clinical use (i.e., administration of this product or any material using this product to humans) or the right to implant any material made using this product into an animal by, or in collaboration with, a for-profit entity, for purposes other than basic pre-clinical research applications (including without limitation teratoma assays) to validate the function of the cells. Purchasers who do not agree to the terms and conditions set forth above should return the product in acceptable conditions to the seller for a refund.

Quality Statement:

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.